Over the last 12 years, insiders at Biomerica have traded over $80,900 worth of Biomerica stock and bought 151,277 units worth $334,788 . The most active insiders traders include Mark A Sirgo, David Moatazedi, and John P. Kenny. On average, Biomerica executives and independent directors trade stock every 61 days with the average trade being worth of $3,349. The most recent stock trade was executed by Zackary S. Irani on 25 May 2023, trading 700 units of BMRA stock currently worth $1,113.
biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh
Biomerica executives and other stock owners filed with the SEC include: